SecBot SecBot
SECBOTREPLAY Home › Report › ABEO

ABEO · Q3 ZEVASKYN rev +18% seq

Abeona Therapeutics Inc. · PRESS-RELEASE filed Nov 9, 2026 at 06:35 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 9, 2026 at 06:35 ET

Abeona Therapeutics reported Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially, with a net loss of -$0.08 per share, beating the consensus EPS estimate of -$0.17. The company also announced a $30M PIPE financing and the acquisition of Phase 3-ready ABO-801 for EoE, which together dilute existing shareholders by approximately 13-15%.

  • Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially from $11.4M in Q2 2026
  • Net loss of $(4.8)M or $(0.08) per share, compared to consensus EPS estimate of $(0.17)
  • Cash, cash equivalents and short-term investments of $134.9M as of September 30, 2026
  • Separately announced $30M PIPE financing at $3.75 per share and acquisition of ABO-801 for $20M in stock

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access